共 21 条
- [1] Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM)JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)Uemura, Marc IsamuHaymaker, Cara L.Murthy, RaviJames, MarihellaCornfeld, MarkChunduru, SrinivasAgrawal, SudhirYee, CassianWargo, Jennifer A.Amaria, Rodabe NavrozePatel, Sapna PradyumanTawbi, Hussein Abdul-HassanGlitza, Isabella ClaudiaWoodman, Scott EricHwu, Wen-JenDavies, Michael A.Hwu, PatrickOverwijk, Willem W.Bernatchez, ChantaleDiab, Adi
- [2] Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II studyANNALS OF ONCOLOGY, 2018, 29Diab, A.Haymaker, C.Bernatchez, C.Andtbacka, R. H. I.Shaheen, M.Johnson, D.Markowitz, J.Puzanov, I.Murthy, R.Johnson, D. H.James, M.Chunduru, S.Geib, J.Swann, S.Rahimian, S.Hwu, P.
- [3] ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanomaANNALS OF ONCOLOGY, 2018, 29Ascierto, P. A.Arenberger, P.Atkinson, V. G.Hansson, J.Kapiteijn, E.Loquai, C.Negrier, S.Shaw, H. M.Tarhini, A.Walker, J.Geib, J.Rahimian, S.Swann, S.Diab, A.
- [4] A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanomaANNALS OF ONCOLOGY, 2017, 28Diab, A.Haymaker, C.Uemura, M.Murthy, R.James, M.Geib, J.Cornfeld, M.Swann, S.Yee, C.Wargo, J.Amaria, R.Patel, S.Tawbi, H.Glitza, I.Woodman, S.Hwu, W-J.Davies, M. A.Overwijk, W.Bernatchez, C.Hwu, P.
- [5] TLR9 agonist harnesses innate immunity to drive tumor-infiltrating T cell expansion in distant lesions in a phase 1/2 study of intratumoral IMO-2125+ipilimumab in anti-PD1 refractory melanoma patientsJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5Haymaker, CaraUemura, MarcHwu, Wen-JenMurthy, RaviJames, MarihellaBhatta, AnkitBentebibel, Salah EddineBrevard, JulieGeib, JamesLipford, KathrynCornfeld, MarkChunduru, SrinivasYee, CassianWoodman, ScottAmaria, RodabePatel, SapnaTawbi, HusseinOliva, Isabella GlitzaDavies, MichaelOverwijk, WillemHwu, PatrickBernatchez, ChantaleDiab, Adi
- [6] Intratumoral administration of IMO-2125, a novel TLR9 agonist, modulates the tumor microenvironment and exerts systemic antitumor activity alone and in combination with an anti-CTLA-4 mAbCANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)Wang, DaqingZhu, FugangMao, XianzhiAgrawal, Sudhir
- [7] A PHASE 1, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-ESCALATION STUDY OF IMO-2125, A TLR9 AGONIST, IN HEPATITIS C-NONRESPONDERSJOURNAL OF HEPATOLOGY, 2010, 52 : S14 - S14Muir, A.Ghalib, R.Lawitz, E.Patel, K.Rodriguez-Torres, M.Sheikh, A.Sapp, S.Taylor, R.Bexon, A.Sullivan, T.Dovholuk, A.McHutchison, J.
- [8] Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanomaCANCER RESEARCH, 2017, 77Haymaker, CaraUemura, MarcMurthy, RaviJames, MarihellaWang, DaqingBrevard, JulieSwann, SuzanneGeib, JamesCornfeld, MarkChunduru, SrinivasAgrawal, SudhirYee, CassianWargo, JenniferAmaria, RodabePatel, SapnaTawbi, HusseinGlitza, IsabellaWoodman, ScottHwu, Wen-JenDavies, Michael A.Hwu, PatrickOverwjik, WillemBernatchez, ChantaleDiab, Adi
- [9] Creating the tumor microenvironment for effective immunotherapy: Antitumor activity of intratumoral IMO-2125, a TLR9 agonist is further enhanced by inhibition of indoleamine-pyrrole 2,3-dioxygenase (IDO)CANCER RESEARCH, 2016, 76Wang, DaqingJiang, WayneLakshmi, BhagatDiMuzio, JillianZhu, FugangAgrawal, Sudhir
- [10] Phase 2 study to evaluate efficacy and safety of combination therapy with nivolumab (NIVO) and ipilimumab(IPI) in patients with previously untreated melanomaANNALS OF ONCOLOGY, 2017, 28Kiyohara, Y.Takenouchi, T.Uhara, H.Koga, H.Uchi, H.Yamazaki, N.